AustralianSuper Pty Ltd Cuts Stake in United Therapeutics Corporation $UTHR

AustralianSuper Pty Ltd lessened its stake in United Therapeutics Corporation (NASDAQ:UTHR) by 66.0% during the 3rd quarter, according to its most recent disclosure with the SEC. The institutional investor owned 98,000 shares of the biotechnology company’s stock after selling 189,845 shares during the quarter. AustralianSuper Pty Ltd owned approximately 0.23% of United Therapeutics worth $41,083,000 at the end of the most recent reporting period.

Other hedge funds and other institutional investors have also recently modified their holdings of the company. Geneos Wealth Management Inc. lifted its stake in United Therapeutics by 141.7% in the 1st quarter. Geneos Wealth Management Inc. now owns 145 shares of the biotechnology company’s stock worth $45,000 after purchasing an additional 85 shares in the last quarter. Envestnet Asset Management Inc. increased its holdings in shares of United Therapeutics by 1.6% in the second quarter. Envestnet Asset Management Inc. now owns 73,072 shares of the biotechnology company’s stock worth $20,995,000 after purchasing an additional 1,163 shares during the last quarter. Hantz Financial Services Inc. lifted its position in shares of United Therapeutics by 1,950.0% in the second quarter. Hantz Financial Services Inc. now owns 246 shares of the biotechnology company’s stock worth $71,000 after buying an additional 234 shares in the last quarter. Atria Investments Inc lifted its position in shares of United Therapeutics by 12.6% in the second quarter. Atria Investments Inc now owns 945 shares of the biotechnology company’s stock worth $272,000 after buying an additional 106 shares in the last quarter. Finally, Hussman Strategic Advisors Inc. boosted its stake in United Therapeutics by 16.7% during the second quarter. Hussman Strategic Advisors Inc. now owns 14,700 shares of the biotechnology company’s stock valued at $4,224,000 after buying an additional 2,100 shares during the last quarter. Institutional investors own 94.08% of the company’s stock.

Analysts Set New Price Targets

Several analysts have recently issued reports on UTHR shares. Weiss Ratings reaffirmed a “buy (b)” rating on shares of United Therapeutics in a report on Monday, December 29th. UBS Group restated a “buy” rating on shares of United Therapeutics in a research report on Tuesday, February 17th. HC Wainwright increased their price objective on shares of United Therapeutics from $525.00 to $600.00 and gave the company a “buy” rating in a research report on Thursday, February 26th. Jefferies Financial Group restated a “buy” rating on shares of United Therapeutics in a report on Monday. Finally, Oppenheimer upped their target price on shares of United Therapeutics from $575.00 to $600.00 and gave the company an “outperform” rating in a research report on Thursday, February 26th. Nine research analysts have rated the stock with a Buy rating and three have given a Hold rating to the company’s stock. According to data from MarketBeat, United Therapeutics currently has an average rating of “Moderate Buy” and an average target price of $533.55.

Trending Headlines about United Therapeutics

Here are the key news stories impacting United Therapeutics this week:

• Positive Sentiment: Phase 3 ADVANCE OUTCOMES met its primary endpoint — ralinepag reduced risk of clinical worsening by ~55% versus placebo, a statistically strong outcome that materially improves the drug’s commercial and regulatory outlook. Business Wire: United Therapeutics Announces Ralinepag Achieved 55% Reduction
• Positive Sentiment: Multiple outlets report the trial also met key secondary endpoints and the company plans an FDA filing process (targeted in 2026), which can drive longer‑term upside if regulatory/label outcomes are favorable. Reuters: United Therapeutics’ blood pressure drug meets main, secondary goals
• Neutral Sentiment: Company investor outreach is increasing — presentations and transcripts at Leerink and the TD Cowen conference provide management detail and help set expectations but are informational rather than immediately value‑creating. Yahoo Finance: United Therapeutics to Present at Leerink
• Neutral Sentiment: Detailed conference/transcript coverage of the ADVANCE OUTCOMES readout is available (useful for modeling uptake, safety profile and timelines). Seeking Alpha: Discusses Phase III ADVANCE OUTCOMES Clinical Trial Results
• Neutral Sentiment: Analysts are updating models — a recent note/estimate for Q1 from HC Wainwright highlights growing focus on near‑term guidance and how the company translates the readout into commercial forecasts. American Banking News: Q1 Earnings Estimate for UTHR
• Negative Sentiment: Near‑term selling pressure likely reflects profit‑taking and skepticism about how quickly ralinepag will drive revenue — the company’s most recent quarter beat EPS but missed revenue expectations, leaving short‑term upside dependent on color from management on timing, labeling and launch plans.

Insiders Place Their Bets

In other United Therapeutics news, COO Michael Benkowitz sold 22,500 shares of the company’s stock in a transaction on Monday, December 15th. The stock was sold at an average price of $496.30, for a total value of $11,166,750.00. The sale was disclosed in a filing with the SEC, which is available at the SEC website. Also, CFO James Edgemond sold 21,000 shares of United Therapeutics stock in a transaction on Monday, December 8th. The stock was sold at an average price of $478.60, for a total value of $10,050,600.00. Following the sale, the chief financial officer owned 8,142 shares of the company’s stock, valued at approximately $3,896,761.20. This trade represents a 72.06% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. In the last 90 days, insiders have sold 356,454 shares of company stock valued at $172,894,963. 10.30% of the stock is owned by company insiders.

United Therapeutics Trading Down 3.0%

UTHR stock opened at $498.65 on Wednesday. United Therapeutics Corporation has a 12 month low of $266.98 and a 12 month high of $537.19. The stock has a market cap of $21.86 billion, a PE ratio of 17.87, a P/E/G ratio of 1.84 and a beta of 0.84. The company has a 50-day moving average price of $484.14 and a 200 day moving average price of $450.62.

United Therapeutics (NASDAQ:UTHR) last announced its earnings results on Wednesday, February 25th. The biotechnology company reported $7.70 earnings per share (EPS) for the quarter, beating the consensus estimate of $6.78 by $0.92. United Therapeutics had a return on equity of 19.30% and a net margin of 41.94%.The business had revenue of $790.20 million during the quarter, compared to analyst estimates of $814.80 million. During the same quarter in the previous year, the business earned $6.19 earnings per share. The company’s revenue for the quarter was up 7.4% compared to the same quarter last year. Sell-side analysts forecast that United Therapeutics Corporation will post 24.48 EPS for the current year.

United Therapeutics Company Profile

United Therapeutics Corporation (NASDAQ: UTHR) is a biotechnology company dedicated to the development and commercialization of unique products to address life-threatening illnesses. The company’s primary focus has been on pulmonary arterial hypertension (PAH), where it has launched several therapies designed to improve functional capacity and quality of life for patients. Its marketed products include continuous infusion treprostinil (Remodulin), inhaled treprostinil (Tyvaso), oral treprostinil (Orenitram) and tadalafil (Adcirca), each tailored to different modes of administration and patient needs.